Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 691 to 705 of 2184 results for guidelines

  1. Reslizumab for treating severe eosinophilic asthma (TA479)

    Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.

    Technology appraisal guidance
    Published
    4 October 2017
    View recommendations

    Sections for TA479

  2. Cellulitis and erysipelas: antimicrobial prescribing (NG141)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    27 September 2019
    View recommendations

    Sections for NG141

  3. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  4. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  5. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19. 

    Withdrawn guideline

  6. About our guidance

    Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.

  7. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.

    Highly specialised technologies guidance
    Published
    28 January 2015
    View recommendations

    Sections for HST1

  8. Bronchial thermoplasty for severe asthma (HTG494)

    Evidence-based recommendations on bronchial thermoplasty for severe asthma in adults. This involves applying heat to the inside walls of the airways.

    HealthTech guidance
    Published
    19 December 2018
    View recommendations

    Sections for HTG494

  9. Patiromer for treating hyperkalaemia (TA623)

    Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.

    Technology appraisal guidance
    Published
    13 February 2020
    View recommendations

    Sections for TA623

  10. Key question: caring

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  11. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

  12. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  15. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance